Welcome!

News Feed Item

PharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022

LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

PharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022

http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_hemophilia_us_drug_forecast_market_analysis_2022.html

PharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022

Summary

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

The US is the largest hemophilia market, due to the high rates of disease diagnosis combined with high rates of primary rFVIII and rFIX prophylaxis among diagnosed severe hemophilia A and B patients. GlobalData anticipates that companies such as Baxter, Bayer, Novo Nordisk, CSL Behring and Biogen Idec will be able to command slight premiums over currently marketed recombinant standard of care therapies, thus contributing to overall market growth.

Scope

- Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Hemophilia A and B market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the US
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 11
2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 13
2.3 Upcoming Related Reports 15
3 Disease Overview 16
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 17
3.1.3 Prognosis and Quality of Life 19
3.2 Symptoms 21
3.2.1 Hemophilia A and B 21
3.2.2 Inhibitors 22
4 Disease Management 23
4.1 Treatment Overview 23
4.1.1 Hemophilia A and B Diagnosis 24
4.1.2 Hemophilia A and B Treatment 24
4.1.3 Inhibitors Diagnosis 26
4.1.4 Inhibitors Treatment 26
4.2 US 28
4.2.1 Clinical Practice 28
5 Competitive Assessment 31
5.1 Overview 31
5.2 Strategic Competitive Assessment 32
5.3 Product Profiles - Major Brands, Hemophilia A 36
5.3.1 Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 36
5.3.2 Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant)) 40
5.3.3 Xyntha/ReFacto AF (moroctocog alfa; Antihemophilic Factor [Recombinant], Plasma/Albumin-Free) 43
5.3.4 Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 46
5.4 Product Profiles - Hemophilia B 48
5.4.1 BeneFIX (nonacog alfa; coagulation factor IX [recombinant]) 48
5.4.2 Rixubis (BAX-326) 51
5.5 Product Profiles - Hemophilia A and B with Inhibitors 54
5.5.1 NovoSeven RT (coagulation factor VIIa [recombinant]) 54
6 Opportunity and Unmet Need 57
6.1 Overview 57
6.2 Opportunities Analysis 58
6.2.1 Longer-Lasting Recombinant Factors to Reduce the Frequency of Prophylactic Injections 58
6.2.2 Lower-Cost Recombinant Replacement Therapies 59
6.2.3 Lower Risk of Inhibitor Formation in Previously Untreated Patients 60
6.2.4 More Convenient Drug Administration 60
6.2.5 Oral Formulation of Recombinant Replacement Therapies 61
6.3 Unmet Needs Gap Analysis 62
6.3.1 Long-Acting FVIII Replacement Therapies 62
6.3.2 Gene Therapy Treatments for Hemophilia A and B 62
7 Pipeline Assessment 63
7.1 Overview 63
7.2 Promising Drugs in Clinical Development - Hemophilia A 63
7.2.1 Eloctate (rFVIII-Fc) (recombinant factor VIII fusion protein) 66
7.2.2 BAY 94-9027 (octocog alfa) 72
7.2.3 BAX-855 75
7.2.4 Novoeight (turoctocog alfa; NN7008) 79
7.2.5 N8-GP (NN7088) 83
7.2.6 CSL-627 (rFVIII-SC) 86
7.3 Promising Drugs in Clinical Development - Hemophilia B 90
7.3.1 Alprolix (rFIXFc) 92
7.3.2 CSL-654 (rIX-FP) 96
7.3.3 N9-GP (NN-7999) 99
7.3.4 IB1001 (trenacog alfa) 102
7.4 Promising Drugs in Clinical Development - Hemophilia A and B Patients with Inhibitors 106
7.4.1 BAX-817 (rFVIIa BI) 107
8 Market Outlook 110
8.1 US 110
8.1.1 Forecast 110
8.1.2 Key Events 114
8.1.3 Drivers and Barriers 114
9 Appendix 117
9.1 Bibliography 117
9.2 Abbreviations 130
9.3 Methodology 133
9.4 Forecasting Methodology 133
9.4.1 Diagnosed Hemophilia Patients 134
9.4.2 Percent Drug-Treated Patients 134
9.4.3 Drugs Included in Each Therapeutic Class 134
9.4.4 Launch and Patent Expiry Dates 135
9.4.5 General Pricing Assumptions 135
9.4.6 Individual Drug Assumptions 136
9.4.7 Pricing of Pipeline Agents 139
9.5 Physicians and Specialists Included in this Study 140
9.6 About the Authors 142
9.6.1 Authors 142
9.6.2 Global Head of Healthcare 143
9.7 About GlobalData 144
9.8 Disclaimer 144

1.1 List of Tables

Table 1: Symptoms of Hemophilia A and B 22
Table 2: Most Prescribed Hemophilia A and B Drugs in the Global Markets, 2013 27
Table 3: Leading Recombinant Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2013 34
Table 4: Leading Plasma-Based Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2012 35
Table 5: Product Profile - Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 37
Table 6: Advate SWOT Analysis, 2013 39
Table 7: Product Profile - Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant)) 41
Table 8: Kogenate FS/Helixate FS SWOT Analysis, 2013 43
Table 9: Product Profile - Xyntha/ReFacto AF (moroctocog alfa; Antihemophilic Factor [Recombinant], Plasma/Albumin-Free) 44
Table 10: Xyntha/ReFacto AF SWOT Analysis, 2013 45
Table 11: Product Profile - Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 46
Table 12: Recombinate SWOT Analysis, 2013 47
Table 13: Product Profile - BeneFIX (nonacog alfa; coagulation factor IX [recombinant]) 49
Table 14: BeneFIX SWOT Analysis, 2013 51
Table 15: Product Profile - Rixubis (BAX-326) 52
Table 16: Rixubis SWOT Analysis, 2013 54
Table 17: Product Profile - NovoSeven RT (coagulation factor VIIa [recombinant]) 55
Table 18: NovoSeven RT SWOT Analysis, 2013 56
Table 19: Overall Unmet Needs - Current Level of Attainment 58
Table 20: Hemophilia A - Phase I/II Pipeline, 2013 63
Table 21: Hemophilia A - Phase III Pipeline, 2013 64
Table 22: Product Profile - Eloctate (rFVIII-Fc) 67
Table 23: Eloctate SWOT Analysis, 2013 71
Table 24: Product Profile - BAY 94-9027 72
Table 25: BAY 94-9027 SWOT Analysis, 2013 75
Table 26: Product Profile - BAX-855 76
Table 27: BAX-855 SWOT Analysis, 2013 78
Table 28: Product Profile - Novoeight (turoctocog alfa; NN7008) 79
Table 29: Novoeight SWOT Analysis, 2013 82
Table 30: Product Profile - N8-GP (NN7088) 83
Table 31: N8-GP SWOT Analysis, 2013 86
Table 32: Product Profile - CSL-627 (rFVIII-SC) 87
Table 33: CSL-627 SWOT Analysis, 2013 89
Table 34: Hemophilia B - Phase I/II Pipeline, 2013 90
Table 35: Hemophilia B - Phase III Pipeline, 2013 90
Table 36: Product Profile - Alprolix (rFIXFc) 92
Table 37: Alprolix SWOT Analysis, 2013 95
Table 38: Product Profile - CSL-654 96
Table 39: CSL-654 SWOT Analysis, 2013 99
Table 40: Product Profile - N9-GP 100
Table 41: N9-GP SWOT Analysis, 2013 102
Table 42: Product Profile - IB1001 103
Table 43: IB1001 SWOT Analysis, 2013 106
Table 44: Hemophilia A and B with Inhibitors - Phase I/II Pipeline, 2013 106
Table 45: Hemophilia A and B with Inhibitors - Phase III Pipeline, 2013 106
Table 46: Product Profile - BAX-817 (rFVIIa BI) 107
Table 47: BAX-817 SWOT Analysis, 2013 109
Table 48: Sales Forecasts ($m) for Hemophilia A and B in the US, 2012-2022 112
Table 49: Key Events Impacting Sales for Hemophilia A and B in the US, 2013 114
Table 50: US Hemophilia A and B Market - Drivers and Barriers, 2013 114
Table 51: Product Launch Dates 135
Table 52: Physicians Surveyed 140

1.2 List of Figures

Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in Hemophilia A, 2012-2022 65
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Hemophilia B, 2012-2022 91
Figure 3: Sales for Hemophilia A and B in the US by Drug Class, 2012-2022 113


Read the full report:
PharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022

http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_hemophilia_us_drug_forecast_market_analysis_2022.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DevOps promotes continuous improvement through a culture of collaboration. But in real terms, how do you: Integrate activities across diverse teams and services? Make objective decisions with system-wide visibility? Use feedback loops to enable learning and improvement? With technology insights and real-world examples, in his general session at @DevOpsSummit, at 21st Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, explored how leading organizations use data-driven DevOps to close th...
"Digital transformation - what we knew about it in the past has been redefined. Automation is going to play such a huge role in that because the culture, the technology, and the business operations are being shifted now," stated Brian Boeggeman, VP of Alliances & Partnerships at Ayehu, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
The past few years have brought a sea change in the way applications are architected, developed, and consumed—increasing both the complexity of testing and the business impact of software failures. How can software testing professionals keep pace with modern application delivery, given the trends that impact both architectures (cloud, microservices, and APIs) and processes (DevOps, agile, and continuous delivery)? This is where continuous testing comes in. D
"WineSOFT is a software company making proxy server software, which is widely used in the telecommunication industry or the content delivery networks or e-commerce," explained Jonathan Ahn, COO of WineSOFT, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
Mobile device usage has increased exponentially during the past several years, as consumers rely on handhelds for everything from news and weather to banking and purchases. What can we expect in the next few years? The way in which we interact with our devices will fundamentally change, as businesses leverage Artificial Intelligence. We already see this taking shape as businesses leverage AI for cost savings and customer responsiveness. This trend will continue, as AI is used for more sophistica...
There is a huge demand for responsive, real-time mobile and web experiences, but current architectural patterns do not easily accommodate applications that respond to events in real time. Common solutions using message queues or HTTP long-polling quickly lead to resiliency, scalability and development velocity challenges. In his session at 21st Cloud Expo, Ryland Degnan, a Senior Software Engineer on the Netflix Edge Platform team, will discuss how by leveraging a reactive stream-based protocol,...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
Sanjeev Sharma Joins June 5-7, 2018 @DevOpsSummit at @Cloud Expo New York Faculty. Sanjeev Sharma is an internationally known DevOps and Cloud Transformation thought leader, technology executive, and author. Sanjeev's industry experience includes tenures as CTO, Technical Sales leader, and Cloud Architect leader. As an IBM Distinguished Engineer, Sanjeev is recognized at the highest levels of IBM's core of technical leaders.
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.
The 22nd International Cloud Expo | 1st DXWorld Expo has announced that its Call for Papers is open. Cloud Expo | DXWorld Expo, to be held June 5-7, 2018, at the Javits Center in New York, NY, brings together Cloud Computing, Digital Transformation, Big Data, Internet of Things, DevOps, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
Digital transformation is about embracing digital technologies into a company's culture to better connect with its customers, automate processes, create better tools, enter new markets, etc. Such a transformation requires continuous orchestration across teams and an environment based on open collaboration and daily experiments. In his session at 21st Cloud Expo, Alex Casalboni, Technical (Cloud) Evangelist at Cloud Academy, explored and discussed the most urgent unsolved challenges to achieve f...
SYS-CON Events announced today that Synametrics Technologies will exhibit at SYS-CON's 22nd International Cloud Expo®, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Synametrics Technologies is a privately held company based in Plainsboro, New Jersey that has been providing solutions for the developer community since 1997. Based on the success of its initial product offerings such as WinSQL, Xeams, SynaMan and Syncrify, Synametrics continues to create and hone inn...
Digital Transformation (DX) is not a "one-size-fits all" strategy. Each organization needs to develop its own unique, long-term DX plan. It must do so by realizing that we now live in a data-driven age, and that technologies such as Cloud Computing, Big Data, the IoT, Cognitive Computing, and Blockchain are only tools. In her general session at 21st Cloud Expo, Rebecca Wanta explained how the strategy must focus on DX and include a commitment from top management to create great IT jobs, monitor ...